These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15960421)

  • 1. [Treatment of diabetes mellitus. New developments and hopes].
    Verspohl EJ
    Med Monatsschr Pharm; 2005 Jun; 28(6):193-202; quiz 203. PubMed ID: 15960421
    [No Abstract]   [Full Text] [Related]  

  • 2. A gut response. The next generation of type 2 drugs.
    Kordella T
    Diabetes Forecast; 2004 Apr; 57(4):39-42. PubMed ID: 15119299
    [No Abstract]   [Full Text] [Related]  

  • 3. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
    Göke B; Hoppe B; Konrad A; Schirra J
    Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of incretins. Type 2 diabetes with new beginnings].
    MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
    [No Abstract]   [Full Text] [Related]  

  • 5. [Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
    MMW Fortschr Med; 2005 Aug; 147(31-32):54-5. PubMed ID: 16128202
    [No Abstract]   [Full Text] [Related]  

  • 6. Theratechnologies expands peptide portfolio in endocrinology.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):734. PubMed ID: 12458565
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
    Rachman J
    Diabet Med; 2004 Jan; 21 Suppl 1():18-20. PubMed ID: 15088933
    [No Abstract]   [Full Text] [Related]  

  • 8. Beyond glycemic control: the role of incretin hormones.
    Ridge TD
    J Am Acad Nurse Pract; 2007; 19(11 Suppl 1):11-4. PubMed ID: 18341243
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel "second-generation" approaches for the control of type 2 diabetes.
    Rotella DP
    J Med Chem; 2004 Aug; 47(17):4111-2. PubMed ID: 15293978
    [No Abstract]   [Full Text] [Related]  

  • 10. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.
    Knudsen LB
    J Med Chem; 2004 Aug; 47(17):4128-34. PubMed ID: 15293981
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 12. Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as "incretin mimetics" that can enhance your blood glucose control.
    Clark WL
    Diabetes Self Manag; 2006; 23(1):36, 39-40. PubMed ID: 16453919
    [No Abstract]   [Full Text] [Related]  

  • 13. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration.
    Ruggles JA; Kelemen D; Baron A
    Endocrinol Metab Clin North Am; 2004 Mar; 33(1):239-52, xii. PubMed ID: 15053905
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hepatogenic diabetes--the current concepts of its pathophysiology and therapy].
    Siegel EG; Gallwitz B; Schmidt WE; Fölsch UR
    Dtsch Med Wochenschr; 1999 Dec; 124(50):1530-5. PubMed ID: 10633781
    [No Abstract]   [Full Text] [Related]  

  • 16. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.
    Larsen PJ; Holst JJ
    Regul Pept; 2005 Jun; 128(2):97-107. PubMed ID: 15780429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies for the pharmacological management of type 2 diabetes.
    Nourparvar A; Bulotta A; Di Mario U; Perfetti R
    Trends Pharmacol Sci; 2004 Feb; 25(2):86-91. PubMed ID: 15102494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1: target for a new class of antidiabetic agents?
    Edwards CM
    J R Soc Med; 2004 Jun; 97(6):270-4. PubMed ID: 15173327
    [No Abstract]   [Full Text] [Related]  

  • 20. Incretin hormones and insulin sensitivity.
    Hansen PA; Corbett JA
    Trends Endocrinol Metab; 2005; 16(4):135-6. PubMed ID: 15860408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.